Kringle Pharma, Inc. (TYO:4884)
Japan · Delayed Price · Currency is JPY 380.00
+3.00 (0.80%)
Feb 17, 2026, 10:41 AM JST
Kringle Pharma Revenue
Kringle Pharma had revenue of 18.57M JPY in the quarter ending December 31, 2025, with 2.25% growth. This brings the company's revenue in the last twelve months to 72.62M, down -8.66% year-over-year. In the fiscal year ending September 30, 2025, Kringle Pharma had annual revenue of 72.00M, down -10.00%.
Revenue (ttm)
72.62M
Revenue Growth
-8.66%
P/S Ratio
37.96
Revenue / Employee
4.27M
Employees
17
Market Cap
2.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 72.00M | -8.00M | -10.00% |
| Sep 30, 2024 | 80.00M | 11.00M | 15.94% |
| Sep 30, 2023 | 69.00M | -322.00M | -82.35% |
| Sep 30, 2022 | 391.00M | 102.00M | 35.29% |
| Sep 30, 2021 | 289.00M | -178.00M | -38.12% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.89B |
| Kohjin Bio | 5.07B |
| Soiken Holdings | 4.58B |
| PhoenixBio | 1.60B |
| Carna Biosciences | 579.06M |
| D. Western Therapeutics Institute | 387.00M |
| Noile-Immune Biotech | 5.00M |
| FunPep Company | 3.00M |